Insights
Insights From Our Experts
Articles
A New Standard for Copay Excellence: How Pharma Can Rethink Affordability
As out‑of‑pocket costs rise and insurance designs grow more complex, traditional copay models are being pushed to their limits. High‑deductible plans, accumulator and maximizer programs, and growing payer and PBM variability are fundamentally reshaping how manufacturer affordability programs operate. In a…
Beyond the Pilot: Scaling the Steep Climb of AI in Drug Safety
Artificial Intelligence in pharmacovigilance often feels like a distant summit for emerging biopharma companies. Many successfully launch a pilot program only to face the harsh operational reality of scaling: crippling capital investment, a scarcity of specialized…
Build the Launch, Then Cut the Deal: A Smarter Playbook for Emerging Biotech Value
For emerging and late-stage biotechs, out-licensing is often viewed as the safer path. Data from our five-year analysis of real-world licensing deal outcomes tells a different story. In this paper, EVERSANA experts break down two critical decisions: Out-license vs. launch independently? If the former, at which stage will out-licensing maximize transactional value? Our experts dive into the key launch…
Stay Ahead of Change with NAVLIN Daily’s Global Policy Watch
Pharmaceutical pricing policy has become increasingly global over the past few years, with changes happening at breakneck pace. The rise of Most-Favored Nation (MFN) in 2025 rapidly accelerated this trend, making it more essential than ever…
Redefining the QA Role in the Age of AI
Artificial intelligence is rapidly transforming Quality Management Systems, from automating document reviews to supporting inspection readiness and risk prediction. While these innovations bring speed and scale, they also introduce new questions around oversight, accountability, and regulatory…
SIUU vs. Unsolicited Off‑Label Requests: A Practical Comparison
As FDA regulatory expectations evolve, distinguishing between SIUU and unsolicited scientific requests is essential. This quick‑reference chart highlights the key differences between these two regulatory pathways (evidence standards, communication pathways, documentation requirements, etc.) so field teams…
The Integrated Advantage: What Medical Affairs Needs Right Now
A New Reality for Medical Affairs Medical Affairs teams are being asked to do more, faster and with fewer resources, amid growing scientific complexity and regulatory scrutiny. The organizations pulling ahead aren’t layering on more vendors or disconnected solutions, they’re adopting an integrated…
Solving The Rare Disease Launch Paradox — Using Pre‑Launch Planning and Partnership to Create Value
Rare disease patients cannot wait – and neither can the companies working to serve them. For emerging biopharma preparing to launch, the stakes have never been higher. Capital constraints, evolving regulatory timelines, and rising expectations from boards and investors are heightening complexity. These pressures intensify in rare disease, where…
EVERSANA’s AI Agency Platform Wins 2026 AI Excellence Award
This is the 5th Consecutive Year EVERSANA Has Been Recognized by the Business Intelligence Group for AI Innovation EVERSANA has been honored with a 2026 Artificial Intelligence Excellence Award, recognized in the Agentic AI category for our best-in-class AI Agency Platform: our end‑to‑end, enterprise‑grade…
It’s Time for Commercialization to Catch Up to Innovation in Women’s Health
The investment landscape for women’s health is finally shifting. After years of chronic underfunding, capital is surging into the category, signaling a decisive market recognition that advancing women’s health is both an unmet need and a…